References : Epilepsy.com/Professionals

WHO IS EPILEPSY.COM/PROFESSIONALS

DONATE

References

Author: GS Hirsch and HS Koplewicz

1. Hoffman H. Struwwelpeter: in English Translation. New York: Dover, 1995;20–23.

2. Still GF. The Goulstonian lectures on some abnormal psychical conditions in children. Lancet 1902;1:1008–1012,1077–1082,1163–1168.

3. Strauss AA, Lehitinen V. Psychopathology and Education of the Brain-Injured Child, vol 1. New York: Grune & Stratton, 1947.

4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (2nd ed). Washington, DC: American Psychiatric Association, 1968.

5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd ed). Washington, DC: American Psychiatric Association, 1980.

6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd ed rev). Washington, DC: American Psychiatric Association, 1987.

7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed). Washington, DC: American Psychiatric Association, 1994.

8. Lahey BB, Applegate B, McBurnett K, et al. DSM-IV Field trials for attention deficit hyperactivity disorder in children and adolescents. Am J Psychiatry 1994;151:1673–1685.

9. Sharp WS, Walter JM, Marsh WL, et al. ADHD in girls: clinical comparability of a research sample. J Am Acad Child Adolesc Psychiatry 1999;38:40–47.

10. Barkley RA, Biederman J. Toward a broader definition of the age-of-onset criterion for attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36:1204–1210.

11. Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36[Suppl]:85S–121S.

12. Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD). NIH Consensus Statement 1998;16(2):1–37. Link to http://consensus.nih.gov/cons/110/110_statement.htm

13. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000;105:5.

14. Achenbach TM. Integrative Guide to the 1991 CBCL, YSR and TRF Profiles. Burlington: University of Vermont, 1991.

15. Conners CK. Conners’ Rating Scales–Revised. New York: Multi-Health Systems, 1997.

16. Reinecke MA, Beebe DW, Stein MA. The third factor of the WISC-III: it’s (probably) not freedom from distractibility. J Am Acad Child Adolesc Psychiatry 1999;38:322–328.

17. Prendergast M, Taylor E, Rapoport JL, et al. The diagnosis of childhood hyperactivity. A U.S.–U.K. cross-national study of DSM-III and ICD-9. J Child Psychol Psychiatry 1988;29:289–300.

18. Bregman JD. Current developments in the understanding of mental retardation: II. Psychopathology. J Am Acad Child Adolesc Psychiatry 1991;20:861–872.

19. Dykens EM. Annotation: psychopathology in children with intellectual disability. J Child Psychol Psychiatry 2000;41:407–417.

20. Baumgardner TL, Reiss AL, Freund LS, Abrams MT. Specification of the neurobehavioral phenotype in males with fragile X syndrome. Pediatrics 1995;95:744–752.

21. Jones KL, Smith DW, Ulleland CN, et al. Pattern of malformation in offspring of chronic alcoholic mothers. Lancet 1973;1(7815):1267–1271.

22. Streissguth A. Fetal Alcohol Syndrome. Baltimore:Paul H. Brookes, 1997.

23. Autti-Ramo I. Twelve-year follow-up of children exposed to alcohol in utero. Dev Med Child Neurol 2000;42(6):406–411.

24. Dykens EM, Rosner BA. Refining behavioral phenotypes: personality-motivation in Williams and Prader-Willi syndromes. Am J Ment Retard 1999;104(2):158–169.

25. Hauser P, Zametkin A, Martinez P, et al. Attention deficit-hyperactivity disorder in people with generalized resistance to thyroid hormone. N Engl J Med 1993;328:997–1001.

26. Elia J, Gulotta C, Rose SR, et al. Thyroid function and attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1994;33:169–172.

27. Spencer T, Biederman J, Wilens T, et al. ADHD and thyroid abnormalities: a research note. J Child Psychol Psychiatry 1995:36:879–885.

28. Fallon BA, Kochevar JM, Gaito A, Nields JA. The underdiagnosis of neuropsychiatric Lyme disease in children and adults. Psychiatr Clin North Am 1998;21:693–703.

29. Brown G, Chadwick O, Shaffer D, et al. A prospective study of children with head injuries: III. Psychiatric sequelae. Psychol Med 1981;11:63–78.

30. Max JE, Robin DA, Lindgren SD, et al. Traumatic brain injury in children and adolescents: psychiatric disorders at two years. J Am Acad Child Adolesc Psychiatry 1997;36:94–102.

31. Gerring JP, Brady KD, Chen A, et al. Premorbid prevalence of ADHD and development of secondary ADHD after closed head injury. J Am Acad Child Adolesc Psychiatry 1998;37:647–654.

32. Hinshaw S, Lahey B, Hart E. Issues of taxonomy and comorbidity in the development of conduct disorder. Dev Psychopathol 1993;5:31–49.

33. Klein RG, Abikoff H, Klass E, et al. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997;54(12):1073–1080.

34. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1997;36:21–29.

35. Disney ER, Elkins IJ, McGue M, Iacono WG. Effects of ADHD, conduct disorder, and gender on substance use and abuse in adolescence. Am J Psychiatry 1999;156:1515–1521.

36. Dykman RA, Ackerman PT. Attention deficits disorder and specific reading disability: separate but often overlapping disorders. J Learn Disabil 1991;24;96–103.

37. Carlson GA. Juvenile mania versus ADHD. J Am Acad Child Adolesc Psychiatry 1999;38:353–354.

38. Biederman J, Klein RG, Pine DS, Klein DF. Resolved: mania is mistaken for ADHD in prepubertal children. J Am Acad Child Adolesc Psychiatry 1998;37:1091–1096.

39. Biederman J, Faraone SV, Mick E, et al. Attention deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry 1996;35:997–1008.

40. Comings DE, Comings BG .Tourette’s syndrome and attention deficit disorder with hyperactivity: are they genetically related? J Am Acad Child Psychiatry 1984;23:138–146.

41. Knell ER, Comings DE. Tourette’s syndrome and attention-deficit hyperactivity disorder: evidence for a genetic relationship. J Clin Psychiatry 1993;54:331–337.

42. Kadesjo B, Gillberg C. Tourette’s disorder: epidemiology and comorbidity in primary school children. J Am Acad Child Adolesc Psychiatry 2000;39:548–555.

43. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 1999;38[Suppl]:32S–54S.

44. Martin A, Scahull L, Klin A, Volkmar F. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry 1999;38:923–931.

45. Perry R. Misdiagnosed ADD/ADHD; rediagnosed PDD. J Am Acad Child Adolesc Psychiatry 1998;37:113–114.

46. Klein R, Mannuzza S. Long-term outcome of hyperactive children: a review. J Am Acad Child Adolesc Psychiatry 1991;30:383–387.

47. Conners CK. Food Additives and Hyperactive Children. New York: Plenum, 1980.

48. Wender EH, Solanto MV. Effects of sugar on aggressive and inattentive behavior in children with attention deficit disorder with hyperactivity and normal children. Pediatrics 1991;88:960–966.

49. Needleman HL, Gunnoe C, Leviton A, et al. Deficits in psychologic and classroom performance of children with elevated dentine lead levels. N Engl J Med 1979;300:689–695.

50. Ernhart CB, Morrow-Tlucak M, Marler MR, et al. Low-level lead exposure in the prenatal and early pre-school periods: early preschool development. Neurotoxicol Teratol 1987;9:259–270.

51. Nanson JL, Hiscock M. Attention deficits in children exposed to alcohol parentally. Alcohol Clin Exp Res 1990;14:656–661.

52. Werner EE, Smith RS. An epidemiological perspective on some antecedents and consequences of childhood mental health problems and learning disabilities. J Am Acad Child Psychiatry 1979;18:292–306.

53. Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1988;44:951–958.

54. Goodman R, Stevenson J. A twin study of hyperactivity: II. The aetiological role of genes, family relationships and perinatal adversity. J Child Psychol Psychiatry 1989;30:691–709.

55. Goodman R, Stevenson J. A twin study of hyperactivity: I. An examination of hyperactivity scores and categories derived from Rutter teacher and parent questionnaires. J Child Psychol Psychiatry 1989;30:671–689.

56. Sherman DK, Iacono WG, McGue MK. Attention-deficit hyperactivity disorder dimensions: a twin study of inattention and impulsivity-hyperactivity. J Am Acad Child Adolesc Psychiatry 1997;36:745–753.

57. Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response [see comments]. J Am Acad Child Adolesc Psychiatry 1999;38(12):1474–1477.

58. Castellanos FX, Giedd JN, Marsh WL, et al. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996;53:607–616.

59. Richters JE, Arnold LE, Jensen PS, et al. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. J Am Acad Child Adolesc Psychiatry 1995;34:987–1000.

60. Weiss M. Psychoeducational intervention with the family, school, and child with attention-deficit hyperactivity disorder. Child Adolesc Psychiatr Clin North Am 1992;1(2):467–479.

61. Abikoff H. An Evaluation of Cognitive Behavior Therapy for Hyperactive Children. In BB Lahey, AE Kazdin (eds), Advances in Clinical Child Psychology, vol 10. New York: Plenum 1987;171–216.

62. Satterfield JH, Satterfield BT, Cantwell DP. Three-year multimodality treatment study of 100 hyperactive boys. J Pediatr 1981;98:650–655.

63. Arnold LE, Abikoff HB, Cantwell DP, et al. National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA): design challenges and choices. Arch Gen Psychiatry 1997;54:865–870.

64. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder. Arch Gen Psychiatry 1999;56:1088-1096.

65. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group, Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999;56:1073–1086.

66. Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry 1937;94:577–585.

67. Solanto MV. Neuropsychopharmacologic mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998;94:127–152.

68. Pelham WE Jr, Swanson JM, Furman MB, Schwindt H. Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures. J Am Acad Child Adolesc Psychiatry 1995;34(11):1504–1513.

69. Shevell M, Schreiber R. Pemoline-associated hepatic failure: a critical analysis of the literature. Pediatr Neurol 1997;16:14–16.

70. Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders? Psychiatry Res 1991;36:141–155

71. Rapport MD, Denney C. Titrating methylphenidate in children with attention-deficit/hyperactivity disorder: Is body mass predictive of clinical response? J Am Acad Child Adolesc Psychiatry 1997;36:523–530.

72. Kent JD, Blader JC, Koplewicz HS, et al. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. Pediatrics 1995;96:320–325.

73. Gittelman R, Mannuzza S. Hyperactive boys almost grown up: III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry 1988;45:1131–1134.

74. Spencer T, Biederman, J, Harding M, et al. Growth deficits in ADHD children revisited: evidence for disorder associated growth delays? J Am Acad Child Adolesc Psychiatry 1996;35:1460–1467.

75. Lowe TL, Cohen TJ, Detlor J, et al. Stimulant medications precipitate Tourette’s syndrome. JAMA 1982;247:1729–1731.

76. Denckla MB, Bemporad JR, MacKay MC. Tics following methylphenidate administration: a report of 20 cases. JAMA 1976;235:1349–1351.

77. Shapiro AK, Shapiro E. Do stimulants provoke, cause or exacerbate tics and Tourette’s syndrome? Compr Psychiatry 1981;22:265–273.

78. Erenberg G, Cruse RP, Rothner AD. Gilles de la Tourette’s syndrome: effects of stimulant drugs. Neurology 1985;35:1346–1348.

79. Gadow KD, Nolan E, Sprafkin J, Sverd J. School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. J Dev Behav Pediatr 1995;16:167–176.

80. Gadow KD, Sverd J. Stimulants for ADHD in child patients with Tourette’s syndrome: the issue of relative risk. J Dev Behav Pediatr 1990;11:269–271.

81. Gadow KD, Sverd J, Sprafkin J, et al. Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 1995;52:444–455.

82. Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 1997;36:589–596.

83. Gadow KD, Sverd J, Sprafkin J, et al. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry 1999;56: 330–336.

84. Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 1999;38:944–951.

85. Zito JM, Safer DJ, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000:283(8):1025–1030.

86. Musten LM, Firestone P, Pisterman S, et al. Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions. J Am Acad Child Adolesc Psychiatry 1997;36:1407–1415.

87. Firestone P, Musten LM, Pisterman S, et al. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1998;8:13–25.

88. Physician’s Desk Reference (53rd ed). Montvale, NJ: Medical Economics, 1999.

89. Gross-Tsur V, Manor O, van der Meere J, et al. Epilepsy and attention deficit hyperactivity disorder: Is methylphenidate safe and effective? J Pediatr 1997;130:670–674.

90. Feldman H, Crumrine P, Handen BL, et al. Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child 1989;143:1081–1086.

91. Gara L, Roberts W. Adverse response to methylphenidate in combination with valproic acid. J Child Adolesc Psychopharmacol 2000;10:39–43.

92. Handen BL, Feldman H, Gosling A, et al. Adverse side effects of methylphenidate among mentally retarded children with ADHD. J Am Acad Child Adolesc Psychiatry 1991;30:241–245.

93. Handen BL, Janosky J, McAuliffe S, et al. Prediction of response to methylphenidate among children with ADHD and mental retardation. J Am Acad Child Adolesc Psychiatry 1994;33:1185–1193.

94. Handen BL, Feldman HM, Lurier A, Murray PJ. Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. J Am Acad Child Adolesc Psychiatry 1999;38:805–812.

95. Hagerman RJ, Murphy M, Wittenberg M. A controlled trial of stimulant medication in children with fragile X syndrome. Am J Med Genet 1988;33:513–518.

96. Birmaher B, Quintana H, Greenhill LL. Methylphenidate treatment of hyperactive autistic children. J Am Acad Child Adolesc Psychiatry 1988;27:248–251.

97. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Adolesc Psychiatry 1985;24:617–629.

98. Leckman JF, Hardin MT, Riddle MA, et al. Clonidine treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1991;48:324–328.

99. Prince JB, Wilens TE, Biederman J, et al. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 1996;35:599–605.

100. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999;38:1551–1559.

101. Swanson J, Flockhart D, Udrea D, et al. Clonidine in the treatment of ADHD: questions about safety and efficacy. J Child Adolesc Psychopharmacol 1995;5:301–304.

102. Fenichel RF. Combining methylphenidate and clonidine: the role of post-marketing surveillance. J Child Adolesc Psychopharmacol 1995;5:155–156.

103. Wilens TE, Spencer TJ, Swanson JM, et al. Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry 1999;38:614–619.

104. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;3:50–54.

105. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention deficit disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409–432.

106. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;35:1314–1321.

107. Olvera RL, Pliszka SR, Luh J, Tatum R. An open trial of venlafaxine in the treatment of attention-deficit/ hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 1996;6:241–250.

108. Zametkin A, Rapoport JL, Murphy DL, et al. Treatment of hyperactive children with monoamine oxidase inhibitors: I. Clinical efficacy. Arch Gen Psychiatry 1985;42:962–966.

From: Hirsch GS and Koplewicz HS. Attention-deficit hyperactivity disorder. In: Devinsky O and Westbrook LE, eds. Epilepsy and Developmental Disabilities. Boston: Butterworth-Heinemann; 2001;187–204.
With permission from Elsevier (www.elsevier.com).
Reviewed June 2004 by Steven C. Schachter, MD, epilepsy.com Editorial Board.